According to a meta‐analysis of 12 randomized clinical trials, the risk of pancreatitis, cholecystitis, MACE‐4 and neoplasms following tirzepatide treatment appears to be comparable to GLP‐1 receptor agonists, placebo or insulin. This evidence concerns the gene INS and pancreatitis.